- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of axitinib on the QT interval in healthy volunteers
Authors
Keywords
Axitinib, QTc interval, Concentration–QTc response modeling, Pharmacokinetics, QT correction for heart rate
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 3, Pages 619-628
Publisher
Springer Nature
Online
2015-01-14
DOI
10.1007/s00280-015-2677-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiac Safety Research Consortium: Can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward
- (2014) Borje Darpo et al. AMERICAN HEART JOURNAL
- The IQ-CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”
- (2013) Borje Darpo et al. ANNALS OF NONINVASIVE ELECTROCARDIOLOGY
- Clinical Pharmacology of Axitinib
- (2013) Ying Chen et al. CLINICAL PHARMACOKINETICS
- Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects
- (2012) Christine E. Garnett et al. AMERICAN HEART JOURNAL
- Toxicities of Targeted Therapy and Their Management in Kidney Cancer
- (2011) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Comparison of QTc Data Analysis Methods Recommended by the ICH E14 Guidance and Exposure–Response Analysis: Case Study of a Thorough QT Study of Asenapine
- (2010) S Chapel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
- (2010) Yazdi K. Pithavala et al. INVESTIGATIONAL NEW DRUGS
- Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
- (2010) Michael A. Tortorici et al. INVESTIGATIONAL NEW DRUGS
- Considerations for Clinical Trial Design and Data Analyses of Thorough QT Studies Using Drug-Drug Interaction
- (2010) Hao Zhu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Creation of a Knowledge Management System for QT Analyses
- (2010) Christoffer W. Tornøe et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Assessing proarrhythmic potential of drugs when optimal studies are infeasible
- (2009) Edwin P. Rock et al. AMERICAN HEART JOURNAL
- Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
- (2009) C. L. Bello et al. CLINICAL CANCER RESEARCH
- Cellular basis of drug-induced torsades de pointes
- (2008) D M Roden BRITISH JOURNAL OF PHARMACOLOGY
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents
- (2008) Nenad Sarapa et al. Expert Opinion On Drug Safety
- Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development
- (2007) Giuseppe Curigliano et al. EUROPEAN JOURNAL OF CANCER
- A Perspective on the Use of Concentration-QT Modeling in Drug Development
- (2007) Tanya Russell et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Concentration-QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review
- (2007) Christin E. Garnett et al. JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation